Spring Bank Announces Collaboration with Gilead

Pharmaceutical Investing

Spring Bank Pharmaceuticals announced a second clinical trial collaboration with Gilead Sciences.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) announced a second clinical trial collaboration with Gilead Sciences for a clinical study examining the use of Spring Bank’s oral selective immunomodulator, SB 9200, co-administered with Gilead’s Vemlidy in chronic Hepatitis B patients.
As quoted in the press release:

“We are excited to be starting a new Phase 2 trial, which will be funded and implemented by Gilead Sciences and has the potential to accelerate the development program of SB 9200 as a potential backbone therapy for treatments focusing on functional cure in HBV,” said Nezam Afdhal M.D., D.Sc., Chief Medical Officer of Spring Bank.

Although direct-acting antiviral drugs are effective in suppressing HBV replication, a functional cure in the treatment of chronic HBV has remained elusive. Spring Bank is developing SB 9200, a novel, selective oral immune-modulator which activates hepatic retinoic acid-inducible gene 1 (RIG-I), for the treatment of chronic HBV with the strategic concept that successful combination therapy for chronic HBV will require immune-modulation for a persistent and durable functional cure. In May 2017, Spring Bank released top-line results from the initial cohort of the Phase 2a segment of the ACHIEVE trial that suggested that a low dose (25mg) of SB 9200 alone may be able to reduce hepatitis B surface antigen (HBsAg) levels in patients with chronic HBV, a critical first step in achieving functional cure.

Click here to read the full press release.

Source: globenewswire.com

The Conversation (0)
×